Autologous stem cell and non-stem cell based therapies is a significant therapeutic intervention that makes use of an individual’s cells which are then cultured and reintroduced into the donor patient’s body. As the stem or non-stem cells come from one’s own blood or bone marrow, it is referred to as autologous therapy. According to FDA, the definition of autologous use is the implantation, transplantation, infusion, or transfer of human cells or tissue back into the individual from whom the cells or tissue were recovered. Autologous stem cell and non-stem cell based therapies are used to treat various bone marrow diseases such as multiple myeloma, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma and aplastic anemia. Other diseases that can be treated with the help of autologous stem cell and non-stem cell based therapies include Parkinson’s disease, thalassemia, diabetes etc. Autologous cell therapies also help in killing cancer cells after high doses of chemotherapy. This autologous therapy allows the patient to have normal bone marrow which gets destroyed during the process of chemotherapy. However, there are certain complications and risks associated with the autologous cell therapy which includes hair loss, diarrhea, nausea, vomiting, severe infections, infertility and heart complications.
Download exclusive Sample of this report:
Based on applications, the autologous stem cell and non-stem cell based therapies market can be segmented as follows:
- Neurodegenerative disorders
- Autoimmune diseases
- Cancer and tumors
- Cardiovascular diseases
- Other infectious diseases
The use of autologous cell therapies in cosmetic surgery is also gaining momentum in the market presently. The therapy has been observed to show long lasting effects as compared to traditional form of treatments. Cosmetic surgery treatment with the help of analogous cell therapy is under intense investigation and would prove to be promising for the future despite various challenges.
Based on geography, the autologous stem cell and non-stem cell based therapies market can be segmented into four major regions: North America, Europe, Asia Pacific and Rest of the World (RoW). Out of these regions, North America holds the largest share in the autologous stem cell and non-stem cell based therapies market followed by Europe. The prime factors which are driving the growth of the market in these regions are minimization of risks associated with autologous cell therapies, and the ability of analogous cell therapy to cure a wide range of infectious diseases. Moreover, autologous cell therapies do not require any cells from an outside donor which leads to least infection transmission. Asia Pacific is the most promising market for the growth of autologous stem cell and non-stem cell therapies due to presence of various emerging economies such as China, Malaysia, Vietnam and India. The factors which would augment the growth of the market in Asia Pacific are various autoimmune and cardiovascular diseases being effectively cured through autologous cell therapies and least risk of infection involved. Other factors such as favorable taxation policy, presence of sophisticated healthcare infrastructures and beneficial reimbursement scenario would accentuate the growth of autologous stem cell and non-stem cell based therapies market in the coming few years.
Various biopharmaceutical companies are developing autologous stem cell and non-cell stem therapies for the treatment of chronic diseases. Some of the major players operating in the autologous stem cell and non-stem cell based therapies market are Aastrom Biosciences, Fibrocell Science, Inc., Dendreon Corporation, BrainStorm Cell Therapeutics, NeoStem, Inc., Regeneus Ltd. and Genzyme Corporation.